普伐他汀对ACS患者外周血炎症细胞因子表达的影响

目的:探讨普伐他汀治疗急性冠状动脉综合征(ACS)的可能作用机制。方法:将ACS患者80例分为治疗组和对照组,每组均为40例。对照组予以常规治疗,治疗组在上述治疗基础上给予口服普伐他汀20mg,1次/d,两组均治疗6个月为1个疗程。结果:两组患者治疗前血浆MMP-9和IL-18含量无明显差异(P>0.05)。治疗1个疗程后,两组患者血浆MMP-9和IL-18水平均较治疗前明显下降(P<0.05或P<0.01),但治疗组下降更加明显(P<0.05)。两组患者治疗前颈动脉彩超检查,颈动脉斑块大小、厚度、数量和颈总动脉中层内膜厚度(IMT)比较基本相似(P>0.05)。治疗1个疗程后,治疗组颈动脉斑块大小、厚度、数量和IMT均较治疗前明显减小(P<0.05),而对照组变化不明显(P>0.05),两组比较差异明显(P<0.05)。结论:普伐他汀对ACS患者外周血MMP-9和IL-18的表达有一定调节作用,从而改善动脉粥样硬化情况影响患者预后。

The Effect of Pravastatin on the Expression of Inflammatory Cytokines from Peripheral Blood of Patients with Acute Coronary Syndrome

Objective To investigate the possible mechanism of pravastatin in treating acute coronary syndrome（ACS）. Methods A total of 80 patients with ACS were randomly divided into the treatment and control groups, with 40 patients in each group. In the control group, conventional treatment was used. Besides, pravastatin was orally administered （20mg, once a day） in the treatment group. Six months of treatment was regarded as one course in both groups. Results There was no significant difference of serum MMP-9 and IL-18 in both groups （P 〉0.05）. After one treating course, both of MMP-9 and IL-18 decreased markedly than before （P 〈 0.05 or P 〈 0.01 ）, which was more obviously in the treatment group （P 〈 0.05 ）. The carotid artery Doppler ultrasound examination showed that plaque area, thickness, numbers and intima-media thickness （IMT） was similar in both groups （P 〉 0.05 ）. After one course of treatment, the plaque area, thickness, numbers and IMT all decreased distinctly than before in the treatment group （ P 〈 O. 05 ） , while such changes were not profoundly in the control group （ P 〉 0.05 ） , but with significant differences between two groups （P 〈 0.05）. Conclusion Pravastatin has certain regulatory effect on serum MMP-9 and IL-18 expression in patients with ACS, thus affecting their prognosis by improving atherosclerosis.